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Abstract
Background: Chronic rhinosinusitis (CRS) is a common source of ill health; 11% of UK adults reported CRS
symptoms in a worldwide population study. Guidelines are conflicting regarding whether antibiotics should be
included in primary medical management, reflecting the lack of evidence in systematic reviews. Insufficient
evidence to inform the role of surgery contributes to a fivefold variation in UK intervention rates. The objective of
this trial is to establish the comparative effectiveness of endoscopic sinus surgery (ESS) or a prolonged course of
antibiotics (clarithromycin) in adult patients with CRS in terms of symptomatic improvement and costs to the
National Health Service compared with standard medical care (intranasal medication) at 6 months.
Methods/design: A three-arm parallel-group trial will be conducted with patients who remain symptomatic after
receiving appropriate medical therapy (either in primary or secondary care). They will be randomised to receive: (1)
intranasal medication plus ESS, (2) intranasal medication plus clarithromycin (250 mg) or (3) intranasal medication
plus a placebo. Intranasal medication (current standard medical care) is defined as a spray or drops of intranasal
corticosteroids and saline irrigations. The primary outcome measure is the SNOT-22 questionnaire, which assesses
disease-specific health-related quality of life. The study sample size is 600. Principal analyses will be according to the
randomised groups irrespective of compliance. The trial will be conducted in at least 16 secondary or tertiary care
centres with an internal pilot at six sites for 6 months.
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Discussion: The potential cardiovascular side effects of macrolide antibiotics have been recently highlighted. The
effectiveness of antibiotics will be established through this trial, which may help to reduce unnecessary usage and
potential morbidity. If ESS is shown to be clinically effective and cost-effective, the trial may encourage earlier
intervention. In contrast, if it is shown to be ineffective, then there should be a significant reduction in surgery
rates. The trial results will feed into the other components of the MACRO research programme to establish best
practice for the management of adults with CRS and design the ideal patient pathway across primary and
secondary care.
Trial registration: ISRCTN36962030. Registered on 17 October 2018.
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Background
Background and rationale
The problem being addressed
Chronic rhinosinusitis (CRS) is a common source of ill
health; 11% of UK adults reported CRS symptoms in a
worldwide population study [1]. Symptoms, including nasal
obstruction, nasal discharge, facial pain, anosmia and sleep
disturbance, have a major impact on quality of life (QoL),
reportedly greater in several domains of the SF-36 than an-
gina or chronic respiratory disease [2]. Acute exacerbations,
inadequate symptom control and respiratory disease ex-
acerbation are common. Complications are rare but may
include visual impairment and intracranial infection. Longi-
tudinal primary-care electronic health records from the
Clinical Practice Research Datalink, a nationally representa-
tive subset of primary-care data across consenting general
practices, show that 1% of UK adults receive treatment for
CRS from their general practitioner (GP) each year, with a
median of four GP visits. They receive multiple medica-
tions, with 91% receiving an antibiotic prescription [3].
Secondary-care electronic health records for 2012/13 from
Hospital Episode Statistics, England’s national administra-
tive billing dataset for hospitals, show that approximately
40,000 sinus operations were performed in England and
Wales, in addition to an estimated 120,000 outpatient con-
sultations [4]. A worldwide study demonstrated that one in
three CRS patients in primary care have poorly controlled
symptoms [5]. The socio-economic cost of CRS is signifi-
cant, with 57% of patients reporting absenteeism and 28%
experiencing associated anxiety and depression [6, 7]. US
businesses report CRS as one of the top 10 illnesses that
cause absence from work [8].
Need and rationale for research in this area
The European Position Paper on Rhinosinusitis and Nasal
Polyps (EPOS 2012) includes treatment guidelines and a
research strategy for CRS, emphasising where limited evi-
dence restricts care [9]. Key elements of this strategy are
addressed herein, including the paucity of randomised
controlled trials (RCTs) of treatments for rhinosinusitis. In
the UK, there are no specific national treatment guidelines
and adherence to EPOS 2012 is variable [10]. A recent
ENT-UK commissioning guideline [11] acknowledges
the lack of high-quality trials and although it does
not recommend routine antibiotic use for CRS in pri-
mary care, GPs often prescribe repeated courses [12],
which may cause resistance. There is growing interest
in the immune-modulating and anti-inflammatory ef-
fects of macrolide antibiotics in treating chronic air-
way inflammatory disease, with low-dose long-term
macrolides being prescribed for their immune re-
sponse and not primarily as anti-bacterial agents [13].
Longer-term antibiotic use in secondary care has a
low-grade recommendation, reflecting conflicting evi-
dence from two RCTs [14, 15], resulting in a call for
further trials [16–18].
First-line therapy is often delivered in primary care,
and consists of initial treatment with intranasal cortico-
steroids, short courses of antibiotics or saline rinses. At
least one in three CRS patients attending ear, nose and
throat (ENT) clinics are considered to have failed this
initial treatment, which is known as appropriate medical
therapy (AMT), and are considered for endoscopic sinus
surgery (ESS) [19, 20]. Insufficient evidence to define the
role of surgery contributes to a fivefold variation in
intervention rates across England, as determined by the
clinical commissioning group [11]. The duration of
symptoms before surgery varies from under 1 to over 10
years [21, 22]. If surgery is less effective than AMT, pa-
tients may be exposed to unnecessary risks and morbid-
ity. If surgery is more effective, current delays reflect
suboptimal patient care. Such uncertainty resulted in the
inclusion of ESS in the Database of Treatment Uncer-
tainties (DUETS) of the National Institute for Health
and Care Excellence (NICE) [23].
As the EPOS 2012 guidelines recommend AMT prior
to surgery, any trial must ensure patients have failed to
respond to an adequate attempt at treatment using
AMT. Intranasal corticosteroids and saline irrigation, for
which there are strong recommendations for use based
on high-quality level 1 evidence, should be included in
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AMT. Guidelines are conflicting regarding whether antibi-
otics should be included in primary medical management,
reflecting the lack of evidence noted above. Our trial uses
a pragmatic approach in which eligibility for surgery is
based on a shared decision between the principal investi-
gator (PI) and the patient, after initial treatment with
AMT, in keeping with current guidelines [9, 24, 25].
Past and current research
Cochrane reviews have recently been completed covering
the treatment options being assessed in this trial [26–31].
They support the use of intranasal corticosteroids and sa-
line irrigations as standard treatment but express the need
for more trials with antibiotics. A systematic review of
ESS commissioned by the Human Tissue Authority iden-
tified the need for high-quality studies comparing surgery
with medical treatment [32, 33]. Updated reviews of the
literature and trial registries have not identified new stud-
ies. One potentially relevant trial reported by DUETS was
never started. Two 2014 Cochrane systematic reviews of
medical and surgical management concluded that further
studies are urgently needed [34, 35]. There is little on-
going research that overlaps with the MACRO
programme. Two relevant antibiotic trials are currently
recruiting. A trial aiming to determine the optimum dur-
ation of longer-term antibiotics in patients with CRS [36]
compared the effectiveness of 3 with 6 weeks of azithro-
mycin but did not include a placebo arm. A commercially
sponsored study compared azithromycin with a placebo in
patients with persistent symptoms after ESS [37], but for
many patients the aim was to avoid primary surgery [38].
Therefore, a trial to determine the effectiveness of antibi-
otics compared with ESS is essential. Finally, an RCT com-
paring ESS with topical medical therapy versus topical
medical therapy alone for a subgroup with CRS with nasal
polyps (CRSwNPs) is underway in the Netherlands [39].
Importance of the research
Despite the burden of CRS, UK health-economic evaluations
are lacking. An American model demonstrates a high eco-
nomic burden to patients, health-care systems and society
[40, 41]. In 2011, CRS cost the US health-care system $8.6
billion with significant direct and indirect costs. Antibiotic
resistance is considered one of the most significant threats to
patient safety in Europe [42]. Evaluating the effectiveness of
antibiotics and promoting appropriate usage is integral to
the UK 5-year antimicrobial resistance strategy [43]. Given
the high prevalence of CRS and the variability in prescribing
antibiotics, this may represent a public health danger
through selective pressure on bacteria and antibiotic resist-
ance. In addition, the potential cardiovascular side effects of
macrolide antibiotics have recently been highlighted [44].
The effectiveness of antibiotics must be urgently established
to reduce unnecessary use and potential morbidity.
International guidelines suggest that patients should receive
the ‘maximum medical therapy’, which usually includes nasal
(and possibly oral) steroids, antibiotic treatment and regular
nasal douching, prior to surgical intervention. However, the
use and duration of antibiotic use is very variable. In total,
91% of CRS patients currently receive an antibiotic prescrip-
tion prior to referral. Recently, some clinical commissioning
groups have insisted on a 3-month trial of macrolide antibi-
otics prior to secondary-care referral [48]; however, evidence
to support this recommendation is lacking.
There is both wide variation in surgical practice and
very high rates of revision surgery [45, 46]. There is a
risk that patients may undergo surgery and its attendant
complications without due reason. In contrast, recent
changes to commissioning that restrict access to sinus
surgery may deny beneficial treatment to patients. The
risk is that limited evidence for effectiveness is assumed
to indicate non-effectiveness, leading to the decommis-
sioning of an effective treatment by clinical commission-
ing groups, with some already deviating widely from
NICE commissioning guidelines [47]. It is essential to
assess rigorously the effectiveness and cost-effectiveness
of surgery to enable robust decision-making from pa-
tient, health service and societal perspectives. In
non-randomised studies, surgery achieves significant im-
provements in health-related QoL and reductions in on-
going health-care utilisation. Pre- and post-trial health
economic modelling will ensure the trial design reflects
current pathways. If ESS is clinically effective and
cost-effective, the trial may encourage earlier interven-
tion. In contrast, if it is shown to be ineffective, there
should be significant reductions in surgery rates.
The MACRO trial forms part of a larger programme of
work, the overarching aims of which are (1) to address the
major deficiencies in the evidence base for CRS manage-
ment, (2) to establish best practice for the management of
adults with CRS and (3) to design the ideal patient path-
way across primary and secondary care.
Objectives
Primary objective
The primary objective is to establish the comparative ef-
fectiveness of a prolonged course of antibiotics (clari-
thromycin) or ESS in adult patients with CRS in terms
of symptomatic improvements and costs to the National
Health Service (NHS), compared with standard medical
(intranasal medication) care at 6 months.
Secondary objectives
The secondary objectives are:
 To measure clinical effectiveness using subjective
self-report ratings and objective clinical measures
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 To compare the clinical effectiveness according to
phenotype: CRS with and without polyps (CRSwNPs
versus CRSsNPs)
 To record the incidence and details of adverse
events (AEs) in all treatment arms that are related
to the trial medication or surgery intervention
 To establish the cost-effectiveness and cost utility of
each arm relative to the others over the 6-month
trial
 To embed a mixed-methods evaluation into the
main trial to identify factors and processes necessary
in the implementation of the trial findings
Objectives of internal recruitment pilot phase
The objectives of the internal recruitment pilot phase
are:
 To randomise 72 patients at six pilot sites within 6
months. Recruitment will be deemed successful if
≥75% of the number of patients expected are
recruited (i.e. 54 patients).
 To undertake an embedded qualitative study (the
MACRO Conversation Study) that will identify
recruitment challenges and suggest changes to
optimise recruitment during the main trial phase
Trial design
Overall design
The MACRO trial is a multi-centre three-arm placebo
controlled parallel-group RCT that aims to randomise
600 adult patients with CRS. Patients who remain symp-
tomatic after receiving AMT as deemed suitable by the
local PI or co-investigator (Co-I) (either in primary or
secondary care) and who are considered suitable candi-
dates for further treatment (including surgery) will be
randomised on a 1:1:1 basis to receive:
1. Intranasal medication plus ESS within 6 weeks of
randomisation (ESS group)
2. Intranasal medication plus an initial 2-week course
of capsules with 250 mg of clarithromycin twice
daily followed by a 10-week course of capsules with
250 mg of clarithromycin once daily (antibiotic
group)
3. Intranasal medication plus an initial 2-week course
of placebo capsules twice daily followed by a 10-
week course of placebo capsules once daily (placebo
group)
Intranasal medication (current standard medical care)
is defined as a spray or drops of intranasal corticoste-
roids and saline irrigations as per local formulary guide-
lines. Saline rinses will be provided by a research nurse
(RN). These are non-investigational medicinal products
(NIMPs) (see Name and description of each NIMP).
Internal recruitment pilot phase
For the 6-month internal recruitment pilot phase to
begin, at least three sites should be open. Six sites in
total will be included. An embedded qualitative study
(the MACRO Conversation Study) will be conducted as
part of the pilot phase to identify any challenges to re-
cruitment. The qualitative work will involve
audio-recording of recruitment consultations, and
in-depth interviews with trial staff and patients who have
been approached about participating in the MACRO
trial. The outcomes of the qualitative work will be used
to inform any changes to the design or conduct of the
study, and to identify recruitment strategies or training
needs to optimise recruitment for the main trial phase.
If recruitment is lower than expected, we will propose a
plan to increase recruitment based on the findings from
the MACRO Conversation Study. The progress of this
phase will be communicated regularly with the funder.
Main trial phase
If the pilot phase is successful, further pre-identified
sites will be opened, and all sites will recruit the
remaining participants required to achieve a sample size
of 600 within the funded timescale of the MACRO trial
(estimated total trial duration is 52 months). In terms of
follow-up, work performed by both the research team
[46, 48] and independent researchers [49] has shown
that improvements in QoL remain stable between 6 and
60months. Soler concluded that for clinical trials in-
corporating QoL outcomes, 6 months is considered to
be an appropriate primary end point [49] and therefore,
6 months is the primary end point for this study. Subject
to additional funding, it is proposed to continue the trial
follow-up for a further 40–60months after the initial 52
months’ trial duration, to enable the completion of
long-term follow-up for all participants who have given
their consent (up to 5 years).
Methods/design
Study setting
The trial will be conducted in at least 16 secondary or
tertiary care centres around the UK. The PI at each site
will be a dedicated consultant rhinologist. Details of sites
can be found on the trial website: https://workstream2.
themacroprogramme.org.uk/
Participants
Eligibility of trial participants
Adult patients with CRS for whom symptom control has
not been achieved following previous AMT and who are
considered suitable candidates for further treatment
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(including surgery) will be assessed for eligibility, which
must be assessed by a medically qualified doctor. Only
personnel formally delegated by the PI to assess eligibility
in the trial-specific delegation log may perform this task.
Trial participant inclusion criteria
Participants can be included if they meet all the follow-
ing criteria:
 Adults aged 18 and over with a diagnosis of CRS
according to European guidelines:
A minimum of 12 weeks’ history of inflammation
of the nose and paranasal sinuses characterised by
two or more symptoms, one of which should be
either (1) nasal blockage, obstruction or
congestion or (2) nasal discharge (anterior or
posterior nasal drip). Other symptoms may
include facial pain or pressure and reduction or
loss of smell.
 Nasal endoscopy within the last 3 months to
determine CRS diagnosis and phenotype (CRSwNPs
or CRSsNPs)
 Non-contrast computed tomography (CT) scan
within the last 12 months to determine the Lund–
Mackay score and confirm suitability for ESS
 Moderate or severe symptoms within the last 3
months: SNOT-22 score ≥ 20
 Symptom control not achieved following previous
AMT, as deemed by the local PI or Co-I, and there-
fore considered eligible for ESS
 Knowledge of English sufficient to understand
written and verbal information about the trial, its
consent process and the study questionnaires
Trial participant exclusion criteria
Participants will be excluded if they meet any of the fol-
lowing criteria:
 Lund–Mackay non-contrast CT scan score < 4
 Macrolide antibiotic treatment for >3 continuous
weeks within the last 12 months
 ESS in previous 6 months or visible, open sinus
cavities from previous surgery
 Taking maintenance oral steroids or biologics within
the last 3 months
 Rare or complex sinus conditions, such as CRS
secondary to systemic disease (e.g. ciliary dyskinesias
or granulomatous diseases) or suspected malignancy
 Allergic fungal rhinosinusitis confirmed or suspected
on CT imaging (expansion and mixed density
opacification) necessitating immediate surgery
 Severe asthma (taking high doses of inhaled steroids,
i.e. >1.5 mg per day)
 Females who are pregnant or breastfeeding
 Females of reproductive potential not prepared to
use a reliable means of contraception (e.g. a
hormonal contraceptive patch, intrauterine device,
physical barrier or abstinence, if that is the preferred
and usual lifestyle of the patient) at trial entry
 Females wanting to start a family during the initial
3 months of the trial
 Known immunodeficiency states including HIV and
selective and multiple antibody deficiency states
 Severe septal deviation preventing endoscopic
examination
 Contraindications to surgery (such as a significant
medical co-morbidity)
 Any absolute contraindications to clarithromycin:
risk factors to be assessed at screening include
history of ischaemic heart disease, prolonged QT
interval on an electrocardiogram (ECG), diabetes
and aged over 65, or any medications known to
interact with clarithromycin unless these can be
discontinued during the 3 months of clarithromycin
or placebo treatment
 Known allergies to the investigational medicinal
product (IMP) and excipients of the IMP or the
placebo
 Inability to give consent (significant cognitive
impairment or language issues) or to understand
and comply with trial instructions
 Participation in another trial in the past 4 months
Pre-trial routine assessments to assess eligibility
All patients seen in clinic by the research team will
undergo a routine nasal endoscopy to determine their
CRS diagnosis and phenotype (CRSwNPs or CRSsNPs).
The patients will also be asked to complete a routine
SNOT-22 questionnaire, which is a validated
patient-reported outcome measure (PROM), to deter-
mine the severity of symptoms (score ≥20 needed for
eligibility). Any previous medical therapy will be dis-
cussed, and if symptoms have persisted following AMT
(as deemed by the PI or Co-I) and the patient is
considered suitable for further treatment (including
surgery), a routine CT scan will be requested to confirm
CRS and determine the Lund–Mackay score. The
screening, consent and randomisation flow diagram is
shown in Fig. 1.
Interventions
Name and description of IMPs
UK-licensed 250mg tablets of standard release clarithro-
mycin will be over-encapsulated and provided in two bot-
tles with a blinded label compliant with annex 13 of the
EU GMP guidelines. The first bottle will contain the in-
duction dose (one capsule to be taken orally twice daily
for 2 weeks) and the second bottle will contain the
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remaining capsules, to be taken orally once a day for a fur-
ther 10 weeks. The placebo capsules will also be provided
in matching bottles with randomised, blinded labels.
Choice of antibiotic for the trial
With respect to the choice of antibiotic, we selected a
macrolide, specifically clarithromycin, for several reasons:
 It has both anti-inflammatory and antimicrobial prop-
erties as demonstrated in other respiratory tract
disorders [50–52]. At a dose of 250 mg orally twice
daily, the peak tissue levels 4 h after administration
have been shown to be 8.32 mg/kg ± 2.57 in nasal mu-
cosa, with the drug characteristic being therapeutic
serum concentrations and high tissue concentrations
[53]. As a result, clarithromycin exhibits its immuno-
modulatory effects through inhibition of neutrophilic
inflammation and macrophage activation [54].
 It has good action for typical CRS flora [55]. A dose
of 250 mg twice daily is effective in the treatment of
Fig. 1 In our proposed setup, an automatic body representation is created based on which calculations for movement parameters can be
automatically performed, for example step length, step width, joint angles and walking speed
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respiratory tract organisms, including Moraxella
catarrhalis, Streptococcus pneumoniae,
Staphylococcus aureus and Haemophilus influenzae
(the minimum inhibitory concentration for the 90th
percentile of the isolates is 0.064 mg/L) [56].
 It is currently recommended (Grade C
recommendation) by EPOS and the ENT-UK rhino-
sinusitis commissioning guidelines for selected pa-
tients with CRS [9, 57]
 Although EPOS states that its use should be
restricted to patients who have confirmed CRS on
endoscopic examination, it is increasingly being
recommended that GPs prescribe a prolonged
course to patients without confirmatory endoscopy
in primary care; however, in the MACRO
Programme Workstream 1, health informatics data
showed little evidence that courses lasting longer
than 3 weeks were being prescribed in primary care.
 Two RCTs have produced conflicting results for the
efficacy of macrolides [14, 15], necessitating a trial
that can differentiate according to phenotype.
 Previous studies suggest a longer course of
medication is better [58, 59], although in practice
both duration and compliance vary. We propose to
adopt a 12-week course of clarithromycin within this
trial, giving this study a realistic timeline and recruit-
ment targets.
 Systematic reviews have highlighted that the overall
quality of evidence from previous studies is low due
to limitations in trial designs. A firm conclusion
regarding the effectiveness of macrolides for CRS
could not be reached [26, 60].
 Several publications have raised concerns about the
cardiac toxicity of erythromycin in patients with a
prolonged QT interval [61, 62]. We have selected
clarithromycin since: (1) erythromycin has poor
tolerability, (2) a previous RCT showed that
azithromycin has poor efficacy and (3) there is
limited availability of roxithromycin in the UK.
 Aside from the issues above, clarithromycin is
readily available and has a reasonable side-effect pro-
file (as seen in our feasibility study) [63]
Name and description of each NIMP
A spray or drops of intranasal corticosteroids will be
prescribed for all participants to use throughout the trial,
as per local formulary practice. Saline irrigation packs
will be provided by NeilMed® Pharmaceuticals. Both
concomitant medications are licensed in the UK and
used within their indication. These drugs are considered
to be NIMPs in this trial. Host sites are responsible for
maintaining a system that allows adequate reconstruc-
tion of NIMP movements; these will be recorded on the
case report forms (CRFs).
Concomitant medication
If there is an acute exacerbation of the condition, the par-
ticipant may receive appropriate additional medical treat-
ment as decided by the ENT surgeon or their GP. This
can include oral steroids or full-dose broad-spectrum or
culture-directed antibiotics. Details of these concomitant
medications will be captured in the patient-reported
resource-use diaries (to be completed at baseline and at 3
and 6months). A list of medicinal products contraindi-
cated in the use of IMP is available on request from the
trial manager at macrotrial@nds.ox.ac.uk.
Endoscopic sinus surgery
ESS will be performed by consultant rhinologists accord-
ing to the techniques described by Stammberger, Lund
and Kennedy, with surgery proceeding in a stepwise
fashion through polypectomy (where present), uncinect-
omy, middle meatal antrostomy, ethmoidectomy, with
additional frontal and sphenoid surgery in selected par-
ticipants. The extent of surgery to be performed will be
decided at an individual participant level but recorded
by the operating surgeon as part of the CRF (having first
been documented in the medical notes). Instrumentation
will not be standardised between centres. Surgery can be
undertaken by a registrar under consultant supervision.
As this is a pragmatic trial, there will be no specific fur-
ther standardisation of the ESS procedure at each site.
Treatment schedule
See also the overall trial design described above. Partici-
pants will receive a prescription to take to the pharmacy
for the spray or drops of intranasal corticosteroids and
will receive a 3-month supply to last them until their
next scheduled visit. Participants will also be supplied
with sinus irrigation bottles and sachets provided by
NeilMed Pharmaceuticals Inc (PO Box 2853, Coulsdon,
Surrey, CR5 2WN, United Kingdom). Each site will have
a designated pharmacy lead for the trial, who will be in-
formed by the Surgical Interventions Trials Unit (SITU)
at the University of Oxford of the allocation of each par-
ticipant and their requirement for clarithromycin or a
placebo.
If a participant does not receive surgery within 6 weeks
of randomisation, this is not considered a protocol
non-compliance. The date of surgery will be captured in
the patients’ medical notes and then transcribed onto
the treatment CRF from the medical records.
Dose modifications
There are no dose modifications in the MACRO trial.
Should a patient be unable to tolerate the dose of medi-
cation, they will discontinue treatment but will asked to
continue their participation in the trial (as discussed in
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the section on ‘Stopping trial treatment’). The dosage of
clarithromycin is in line with an open-label study in the
field [64]; 250 mg is a readily available dose. The initial
regimen is for 2 weeks as this is considered to be thera-
peutic in terms of an antibiotic effect. Participants will
then be requested to take 250 mg of clarithromycin once
a day for a further 10 weeks as the key purpose of this
medication in the MACRO trial is immunomodulatory
[52]. A lower dose is suitable for this effect to be exerted
and takes into consideration recent concerns around
cardiovascular morbidity that were addressed by Work-
stream 1 as part of our trial consensus process.
Assessment of IMP and NIMP compliance
Compliance with medical treatment will be recorded in
the weekly compliance diaries completed by the
participants.
Stopping trial treatment
Participants allocated either to the active IMP or placebo
will be requested to carry a card with them at all times,
outlining that they are participating in the MACRO trial.
If a suspected serious interaction (or serious adverse
event (SAE) that is deemed related to the study medica-
tion) occurs in a participant randomised to either clari-
thromycin or the placebo, the attending clinician, PI or
Co-I should tell the participant to stop taking the trial
medication immediately and inform the MACRO trial
office using the secure SITU email address (situ.ox-
ford@nhs.net) from an NHS email account.
If a participant stops taking their trial medication due to
unwanted side effects, the participant must inform the PI,
Co-I, RN or research practitioner (RP) as soon as possible.
The PI, Co-I, RN or RP should then contact the trial office
using the secure email address situ.oxford@nhs.net.
In both cases, the PI, Co-I, RN or RP should first docu-
ment this in the medical notes, and then complete a
change of status CRF detailing that the participant has
stopped taking their trial medication and the reason for
stopping. The CRF should be sent to the MACRO trial of-
fice. The participant will be requested to remain in the
trial and to continue to undertake all follow-up activities,
as per this protocol (even if they are unblinded to their
study treatment). The patient should be asked to return
any unused trial medication at their next follow-up visit.
If the participant is allocated to ESS and the treatment
does not go ahead or is changed part way through (for
clinical reasons), this should first be documented in the
medical notes and a change of status CRF should be
completed. The CRF should be sent to the MACRO trial
office. The participant will be asked to remain in the
trial and to continue to undertake all follow-up activ-
ities, as per this protocol.
A change of status CRF should be completed by the
PI, Co-I, RN or RP and sent to the MACRO trial office
if the patient’s treatment deviates from the allocated
intervention. The participant will be requested to remain
in the trial and to continue to undertake all follow-up
activities, as per this protocol.
Outcomes
The primary outcome is disease-specific health-related
QoL using the SNOT-22 at 6 months.
The secondary outcomes are:
 Endoscopic score (Lund–Kennedy score)
 Grade of polyps (0–3, Lildholdt score)
 Health-related QoL and quality-adjusted life-years
(QALYs), measured by the SF-12v2 and EQ-5D-5 L
questionnaires
 Need for additional treatment (e.g. oral steroids,
antibiotics, etc.)
 Olfactory function measured using Sniffin’ Sticks
 Upper and lower respiratory function, measured
using peak expiratory flow rate and peak nasal
inspiratory flow rate
 Asthma control test (participants with asthma only)
 AEs due to treatment
 Health-care resource use, including medications and
visits to primary and secondary care, recorded using
patient questionnaires
 Number of days of work missed, recorded using
patient questionnaires
 Overall cost and incremental cost per QALY gained,
from the cost perspective of the NHS and personal
social services, calculated using QoL scores
 Budget impact of treatment
Participant timeline
See details of the treatment schedule above and the
participant flow chart in Fig. 1. All participants will be
enrolled in the trial for 6 months from randomisation.
Additional file 1: Appendix 2 shows the visit schedules.
Visit schedule: baseline and follow-up assessments
Once informed consent has been obtained and the ECG
and pregnancy test (where applicable) have confirmed
the participant’s eligibility, a comprehensive baseline as-
sessment will be undertaken:
 Clinical assessments:
o Peak expiratory flow measurement
o Peak nasal inspiratory flow measurement
o Sniffin’ Sticks olfactory test
o Skin prick allergy test (or RAST inhalant screen).
Allergens to be tested for must include house dust
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mites, mixed grass, mixed tree, mixed mould, dog
and cat. Specific allergens are acceptable in place
of mixed tree, mixed grass or mixed mould.
 Blood tests, including full blood count and total
immunoglobin E count (results from blood tests
taken within last the 6 months are acceptable;
however, the participant must not have taken
prednisolone or other oral steroids within 6 weeks
preceding the blood test)
 Eligibility confirmation
 Participant demographics and medical history
The results of these assessments will be recorded in
the baseline CRF (and medical notes if clinically import-
ant) along with data from the routine care pre-screening
assessments:
 Lund–Mackay score from the CT scan
 Lund–Kennedy score from the endoscopy
 Lildholdt polyp grade from the endoscopy
 SNOT-22 score
Participants will be requested to complete three base-
line disease-specific and generic PROMs online during
the baseline clinic visit (the SNOT-22, SF-12v2 and
EQ-5D-5 L questionnaires), as well as an asthma control
test, if they are known to be asthmatic. Participants will
also be requested to complete an initial online baseline
resource-use questionnaire, which will ask them about
their use of health-care services over the last 3 months
before joining the trial. These questionnaires will be
completed online by the participant during the baseline
visit so that a RN or RP is on hand to answer any ques-
tions. If any site has difficulties with offering these ques-
tionnaires online, a paper version is also available.
Following the initial baseline assessment, all participants
in all treatment arms will be followed up in clinic at 3 and
6 months post-randomisation (±7 days). The following
measurements will be undertaken and recorded on a
trial-specific follow-up CRF:
 Nasal endoscopy
 Peak expiratory flow measurement
 Peak nasal inspiratory flow measurement
 Sniffin’ Sticks olfactory test
Women of childbearing potential will not be re-
quested to undertake another pregnancy test at their
3- or 6-month post-randomisation clinic visit. How-
ever, the site should reiterate to the woman that if
pregnancy occurs, a member of the local site staff
should be informed immediately, and a pregnancy
reporting form should be completed and sent to the
central MACRO office.
Participants will be contacted separately by the
MACRO trial office and requested to complete the
SNOT-22, EQ-5D-5 L and SF-12v2 PROM question-
naires electronically at 6 weeks, 3 months and 6months
post-randomisation. Participants will also be asked to
complete an asthma control test (if they are known to be
asthmatic) at 3 and 6months. Those participants who
state at recruitment that they cannot or do not wish to
complete these questionnaires online will be sent the
paper version by the MACRO trial office and requested
to complete the questionnaires and to return them in a
prepaid envelope.
Participants will also be asked to complete a weekly
questionnaire (recording their compliance with intranasal
and placebo or clarithromycin trial-specific medication
usage) and a separate health economics resource-use
questionnaire at baseline, and at 3 and 6months (record-
ing other medication and health-care resource use, and
details of time off work and other costs) to evaluate:
 Need for additional treatment (e.g. oral steroids,
antibiotics, etc.)
 Adverse effects of treatment
 Health-care visits to primary and secondary care
 Number of fays of work missed
 Cost and cost-effectiveness from the perspective of
the NHS and personal social services
 Compliance with the trial medication
A schedule of all trial assessments and procedures is
set out in Additional file 1: Appendix 2. Samples will be
taken for a full blood count and total immunoglobulin E
and will be carried out at local laboratories.
Sample size
The trial will recruit 600 participants. Recruiting partici-
pants from 17 centres (therefore, with 17 ESS surgeons)
is considered a realistic assumption for the following
sample size calculations. The sample size is justified
based upon achieving at least 80% statistical power at
the two-sided 5% significance level. No adjustment for
multiple comparisons has been made, as each of the
treatment comparisons are distinct. The minimum clin-
ically important difference has been estimated to be
about 8.9 points based upon an anchor study [65]. A
10-point difference in SNOT-22 (0.5 standard deviations
(SD), Cohen’s effect size assuming an SD of 20) is often
considered a medium-sized effect size and an important
difference for this type of outcome. A previous study
suggests that a larger effect for surgery against an alter-
native treatment is plausible, as large as 13.8 [31]. Using
target differences of and 8.9 and 10 (and SD of 20)
would require and 107 and 90 per group (331 and 270
overall) to achieve 90% statistical power at the two-sided
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5% significance level. Offsetting this is the possibility of
clustering within the surgical arm, which affects pairwise
comparisons involving surgery, and the need to perform
a subgroup analysis for CRSwNPs versus CRSsNPs par-
ticipants. Allowing for clustering (intraclass correlation
coefficient of 0.05 and 17 clusters of equal size) in the
surgical group would lead to 102 per group (306 overall)
for a target difference of 10 points for 90% power. For
this trial size and using a target difference of 8.9 but an
otherwise identical calculation, there would be 80%
power. To enable secondary analyses of treatment inter-
actions by subgroups with or without polyps, the overall
sample size was inflated to 600 (after allowing for 10%
missing data). This size of study would allow us to detect
a difference of 8.9 and 10 (SD of 20) to be detected in all
CRS patients with >90% power after adjusting for clus-
tering for the main comparisons involving the ESS
group; this is the case even when allowing for the impact
of potential variable cluster sizes (cluster size variance of
49). A study of 600 would also likely provide around
50% and 80% power for testing the treatment interaction
by subgroup (CRSwNPs versus CRSsNPs) for a target
difference of 10 and 13.8, respectively, after allowing for
clustering in the surgical arm and an equivalent variation
in cluster sizes.
Recruitment
Participants in the internal pilot phase: MACRO
Conversation Study
During the internal recruitment pilot phase, potential
trial participants will be invited to take part in an em-
bedded qualitative study (MACRO Conversation Study),
which is designed to evaluate and optimise trial recruit-
ment. All potential participants will receive a separate
participant study information sheet (PIS) for the
MACRO Conversation Study whilst waiting in the out-
patient department (prior to being seen in the clinic).
All participants
Posters and flyers will be placed in outpatient depart-
ments with information about the MACRO trial. All
potential trial participants will be seen in an out-
patient clinic by the PI or Co-I and by the RN or RP,
where the aforementioned routine screening assess-
ments will be carried out and the MACRO trial will
be verbally introduced by the PI or Co-I and RN or
RP. The participant will be informed that in addition
to the routine screening assessments, a trial-specific
ECG scan (to exclude contraindications to clarithro-
mycin) will be undertaken as well as a pregnancy test
(urine test) if the potential participant is of childbear-
ing potential. This information will be included in the
main trial consent form.
If interested in the trial, the patient will be provided
with a copy of the MACRO PIS to take home and re-
view. The PIS will detail the exact nature of the
study, what it will involve for the patient, the implica-
tions and constraints of the protocol, the known side
effects and any risks involved in taking part. It will
be clearly stated that the participant is free to with-
draw from the study at any time for any reason with-
out prejudice to future care, and with no obligation
to give a reason for their withdrawal. In this event,
the choice of treatment will be decided by the patient
and their clinical team.
The RN or RP should update the screening log
and place a MACRO sticker on the notes, to help
identify the patient when they return to the clinic.
All patients will be given sufficient time (a minimum
of 48 h) to consider the trial and to decide if they
would like to take part. Screening logs must be kept
up-to-date and completed fully at all times. They are
sent to the MACRO trial office for a monthly
review.
If the nasal endoscopy and SNOT-22 questionnaire
confirm that the patient is a potential MACRO par-
ticipant but the patient has not received AMT as
deemed by the PI or Co-I, the MACRO trial can still
be introduced and the participant will be given a
copy of the PIS to take home. If, following AMT,
symptom control has not been achieved and further
treatment is deemed necessary, the patient will be
seen in the clinic once more and the MACRO trial
discussed in depth.
Assignment of interventions
Sequence generation
Following consent, once trial eligibility has been con-
firmed, participants will be randomised into the trial by
the PI, Co-I, RN or RP. Participants will be randomly allo-
cated to a treatment option using an automated
web-based secure randomisation system (RRAMP) pro-
vided by the Oxford Clinical Trials Research Unit
(OCTRU) with a 1:1:1 allocation ratio. The algorithm will
stratify by the presence of polyps and centre using per-
muted blocks of varying size. The sequence will be gener-
ated by the trial statistician.
Allocation concealment mechanism and implementation
The centrally managed randomisation will ensure alloca-
tion concealment and prevent selection bias. The partici-
pant’s identifiable information will be recorded on the
randomisation form and will be uploaded to a separate
encrypted database at the University of Oxford. Partici-
pants allocated to receive the placebo or antibiotic will
be assigned a treatment pack number for the corre-
sponding medication. Treatment pack numbers will be
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randomly generated to ensure allocation concealment
and blinding.
Blinding (masking)
Blinding of participants and medical staff will be main-
tained for the comparison of clarithromycin by using a
placebo identical in appearance to the antibiotic, although
the MACRO trial office can reveal the treatment alloca-
tion in case of clinical need. Participants and medical staff
will not be blinded to receiving surgery. At the end of each
trial participant’s follow-up period of 6months, the par-
ticipant will return to normal NHS care. Those who re-
main symptomatic at this point will receive further
treatment as defined by their ENTclinician, which may in-
clude being offered steroids, antibiotics or ESS, depending
on which arm of the trial they were in. Patients who were
allocated to either the placebo or clarithromycin will not
be told of their allocation at the end of their 6-month trial
period, except in an emergency.
If there is a need to treat a patient in an emergency
following a serious adverse reaction (SAR), the treating
PI or medical doctor can break the code using the ran-
domisation system to see if the patient was on the active
drug. Under these exceptional circumstances, the PI or a
member of the site team can unblind the participant
using the clinical trial unit’s in-house RRAMP system. If
unblinding is required for any other reasons apart from
an emergency, site staff must submit a request (through
RRAMP) and the request will be reviewed. If appropri-
ate, it will be approved by a member of the central
MACRO trial office. Where a SAR is not an emergency
to treat but is deemed to be a suspected unexpected ser-
ious adverse reaction (SUSAR), then the clinical trial
unit will break the code for reporting purposes without
necessarily involving the PI. If on breaking the code it is
found that the patient was actually taking the placebo,
the event will not be classed as a SUSAR.
Data collection methods
Confidentiality
All data will be handled in accordance with the General
Data Protection Regulation (EU) 2016/679.
Participants joining MACRO will consent to giving
identifiable information that will include their name,
email address and telephone contact numbers to allow
completion of PROMs and resource-use diaries electron-
ically. If the participant does not consent to completing
the documentation electronically, they will be asked in-
stead to provide their home address and telephone num-
ber so that the MACRO trial office can send the PROM
questionnaires and resource-use diaries by post. This is
coordinated centrally by the MACRO trial office. Partici-
pants’ identifiable information will be kept securely in a
University of Oxford network database, which is separate
to the clinical database.
Upon randomisation, the data will be pseudonymised
and a study number will be given to each participant.
CRFs will not bear the participant’s name, and the study
number will be used for identification. Screening logs
will list the participant’s initials, year of birth and trial
ID to allow identification by site research staff when they
return to the clinic.
Data collection tools and source document identification
Clinical data will be collected from sites on trial-specific
paper CRFs, which will be completed by the local re-
search teams and sent to the MACRO office for data
entry. The data will be entered into a validated installa-
tion of OpenClinica (www.openclinica.com). The data
are held in a secure database and can only be accessed
by authorised users via the OpenClinica application,
which resides on a webserver hosted and managed by
the IT Services Department of Oxford University’s Med-
ical Services Division (http://www.imsu.ox.ac.uk/). Some
CRF data may be entered electronically into LimeSurvey.
Participants will be requested to complete PROM ques-
tionnaires and resource-use diaries electronically using
LimeSurvey every week and every 3 months, respect-
ively. A paper version will also be available for partici-
pants to complete, which can be returned using prepaid
envelopes. Text messaging and email reminders to partici-
pants (who have consented to provide their telephone
numbers and email addresses) who have not returned the
completed PROM questionnaires and resource-use diaries
will be used to maximise the completeness of the data.
The MACRO trial office may also call participants if there
are a number of outstanding PROM questionnaires and
resource-use entries not completed by the participant.
If it becomes clear during the pilot phase that there is a
low return rate for the prospective online weekly compli-
ance diaries, the trial management group (TMG) will dis-
cuss whether to switch to collecting data retrospectively
for this aspect of the trial, i.e. at the 6-week, 3-month and
6-month time points.
Statistical methods
Statistical analysis
Full details of the statistical analysis plan will be agreed
by the MACRO programme steering committee (PSC)
before the data are unblinded. A summary of the
planned analyses is presented here. The primary analysis
will be according to the randomised allocation, irrespect-
ive of subsequent treatment compliance, and conducted
at the two-sided 5% significance level with 95% confi-
dence intervals. No adjustment for multiple comparisons
is planned, as the comparisons relate to distinct clinical
decisions (use or non-use of an antibiotic and surgery
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versus medical management of one form). Baseline data
and participant flow information will be summarised
without a formal analysis. The primary outcome will be
analysed using linear regression adjusted for baseline
SNOT-22 and also for the presence or not of polyps at
baseline. Clustering by surgeon will also be accounted
for where relevant using an appropriate method (e.g. the
cluster robust option in Stata). Secondary outcomes will
be analysed similarly using generalised linear models.
Sensitivity and other planned analyses
The impact of missing primary outcome data will be
assessed in sensitivity analyses, e.g. the multiple imput-
ation approach, as appropriate. Exploratory subgroup
analyses will assess the impact of the presence of polyps
under the treatment effect. The impact of compliance
will be evaluated using a complier average causal effect
approach or a similar approach.
Interim analysis
No interim analyses are anticipated prior to completion
of the follow-up for the designated time points. This is
due to the nature of the trial, the primary outcome and
the desire for reasonable precision to assess the sub-
groups for CRSwNPs and CRSsNPs.
Data monitoring
Details of the committee personnel can be found in
Additional file 1: Appendix 1.
Trial management group
The TMG will include the chief investigator, lead collab-
orative investigator, trial staff and members of the
MACRO programme. A member of the sponsor team
will also be invited to attend. The TMG will be respon-
sible for overseeing the trial. Monthly TMG teleconfer-
ences will take place at the start of the trial, and at least
two face-to-face meetings will take place annually.
The TMG will review recruitment figures, SAEs and
substantial amendments to the protocol prior to submis-
sion to the research ethics committee or the Medicines
and Healthcare Products Regulatory Agency (MHRA).
All PIs will be kept informed of substantial amendments
through their nominated responsible individuals. There
will be a TMG charter for the MACRO trial.
Trial steering committee
As MACRO forms part of a programme of work, there
will be an overarching independent PSC for the duration
of the programme. The PSC contains members experi-
enced in each specialist area of the MACRO
programme. Membership also includes an experienced
triallist, a clinician, a statistician, a qualitative researcher,
a health economist, a GP and a patient. During the
MACRO trial, the PSC will assume the role of the trial
steering committee (TSC) and will provide overall super-
vision of the trial. The TSC will review the recommenda-
tions of the independent data safety and monitoring
committee (DSMC) and, on consideration of this infor-
mation, recommend any appropriate amendments or ac-
tions for the trial as necessary. The TSC acts on behalf
of the funders and sponsor.
Data safety monitoring committee
The role of the DSMC is to provide independent advice
on data and the safety aspects of the trial. The commit-
tee will meet annually to review safety data and any
other issues. There will be a DSMC charter for the
MACRO trial.
Stopping rules
The trial may be stopped before completion for the fol-
lowing reasons:
 On the recommendation of the TSC or DSMC
 On the recommendation of the sponsor and chief
investigator
Discontinuation and withdrawal of participants
Participant withdrawal from trial treatment If a par-
ticipant expresses their wish to withdraw from trial treat-
ment, sites should explain the importance of their
continuing to be followed up for the trial (including com-
pleting the patient-reported trial questionnaires and diaries)
and seek permission to allow use of routine follow-up data
for trial purposes. The importance of the safety follow-up
should be emphasised to the participant in the PIS. If a par-
ticipant decides to withdraw from treatment, this must be
recorded in a change of status CRF and their medical notes.
The participant may withhold their reason for withdrawal.
However, if the participant gives a reason for their with-
drawal from trial treatment, this should be recorded. If a
participant allocated to either of the medical therapy arms
requests to be given a non-trial treatment in addition to or
instead of their trial treatment, this should also be recorded
in the change of status CRF. If the participant wishes to
withdraw from the trial follow-up, a discontinuation
CRF should be completed. Where necessary for safety
(e.g. if the participant requests to receive clarithromy-
cin), they will be unblinded at this point. Permission
to allow data collection to continue will be sought, ir-
respective of the treatment received.
Withdrawal of consent to data collection If a partici-
pant explicitly states that they do not wish to contribute
further data to the trial, their decision must be respected
and recorded in the discontinuation CRF and their
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medical notes. Any data already collected on the patient
will be included in analyses.
Loss to follow-up If a participant moves from the area,
every effort should be made to follow the participant up
at another participating trial site and for this new site to
take over the responsibility for the participant. If a par-
ticipant is lost to follow-up at a site, every effort should
be made to contact the participant’s GP to obtain infor-
mation on their current status.
Replacements
Individuals who do not comply with the treatment
allocation or the study protocol more generally (e.g.
by not attending a clinical visit or completing a
questionnaire) will not be replaced, as the trial is
using an intention-to-treat analysis. Note that a
randomisation error (e.g. incorrectly randomising an
individual a second time) will not be considered a
valid randomisation.
Definition of end of trial
The expected duration of recruitment and follow-up for
the primary outcome data collection point is 52 months
from recruitment of the first patient. For regulatory pur-
poses, the trial will be deemed to have ended when all
data have been received and cleaned and when all quer-
ies have been resolved at each site. Subject to additional
funding, trial follow-up will continue for a further 40–
60months after the initial 52 months’ trial duration, to
enable completion of the long-term follow-up for all
participants who have given their consent (up to 5 years).
For regulatory purposes, the trial will then be deemed to
have ended when all the long-term follow-up data have
been received and cleaned.
Harms
The sponsor’s responsibility for pharmacovigilance has
been delegated to SITU within OCTRU, University of
Oxford. The severity of AEs (for either IMP or ESS) will
be classified as mild (1), moderate (2) or severe (3), as
described in Table 1.
If an event satisfies the definition of a SAE, the PI,
Co-I, RN or RP should complete a paper SAE form.
The following information will be recorded: descrip-
tion, date of onset and end date, severity, assessment
of causality due to trial medication or ESS, other sus-
pect drug or device, and action taken. Follow-up in-
formation should be recorded as necessary. Trial
visits and hospitalisation as part of standard clinical
care will not be reported as an SAE, unless the hospi-
talisation extends beyond the expected length. SAE
forms must be sent via secure email to situ.ox-
ford@nhs.net within 24 h of the local trial team be-
coming aware of the event.
Any SAE or any AE that is more severe than
would be expected that is considered related to the
trial medication or surgery intervention, as judged by
a medically qualified investigator, will be followed,
either until resolution or the event is considered
stable.
Events related to the IMP
The most frequent and common adverse reactions re-
lated to clarithromycin therapy for adults are:
 Abdominal pain
 Diarrhoea
 Nausea
 Vomiting
 Dysgeusia
 Headache
 Insomnia
 Dyspepsia
 Rash
 Hyperhidrosis
 Abnormal liver function test
These adverse reactions are usually mild in intensity
and are consistent with the known safety profile of
macrolide antibiotics. AEs will be recorded in the
hospital notes in the first instance. The clinical symp-
toms of all AEs will be recorded, accompanied by a
simple and brief description of the event, including
dates as appropriate.
Any AE or adverse reaction that occurs after the
baseline assessment (whether as would be expected,
more severe than would be expected or unexpected)
should be recorded. If an event is deemed to be more
severe than would be expected, the PI, Co-I, RN or
RP must complete an AE CRF, otherwise it should be
Table 1 Categories for adverse events
Category Definition
Mild The adverse event does not interfere with the participant’s daily routine and does not require intervention; it causes slight discomfort
Moderate The adverse event interferes with some aspects of the participant’s routine or requires intervention, but is not damaging to health; it
causes moderate discomfort
Severe The adverse event results in an alteration, discomfort or disability that is clearly damaging to health
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detailed in the follow-up CRF at the 3- or 6-month
clinic visit when the patient is seen by the PI, Co-I,
RN or RP.
Events related to ESS
The following AEs are possible following ESS:
 Post-operative bleeding needing nasal packing or
readmission (1 in 200)
 Post-operative infection requiring antibiotics
(1 in 15)
 Bruising around the eye (1 in 500)
 Leakage of cerebrospinal fluid (due to damage to the
skull base, which may lead to meningitis) requiring
repair, either at the time of surgery and delaying the
patient’s discharge or later and causing a re-
admission (1 in 1500)
 Major orbital injury leading to double vision or
blindness (<1 in 10,000)
These events, and all other events relating to the ESS,
will be recorded on the post-procedure CRF. Events oc-
curring after the baseline assessment should be detailed
in the 3- and 6-month post-randomisation follow-up
visit CRF by the PI, Co-I, RN or RP.
Any leak of cerebrospinal fluid leading to meningitis
(and hospitalisation) or major orbital injury leading to
double vision or blindness must be recorded as an SAE.
A delayed discharge for participants undergoing ESS will
not be considered an SAE if the participant’s hospital
stay is less than 24 h.
Auditing
Processing of SAE forms and assessment of expectedness
The trial office will process SAEs as per the instructions
in OCTRU’s relevant standard operating procedure for
safety. SAEs will be reviewed by a nominated person and
any queries clarified with the site. The nominated person
will also perform a central assessment of expectedness.
For SAEs related to the IMP or placebo, expectedness
will be assessed according to the current approved sum-
mary of the product characteristics for clarithromycin.
SUSAR reporting All SUSARs will be reported by SITU
to the relevant competent authority (MHRA) and to the
research ethics committee and other parties as applic-
able. For fatal and life-threatening SUSARs, this will be
done no later than 7 calendar days after the sponsor or
delegate is first made aware of the reaction. Any add-
itional relevant information will be reported within 8
calendar days of the initial report. All other SUSARs will
be reported within 15 calendar days. PIs will be in-
formed of all SUSARs for the relevant IMP for all stud-
ies using the same IMP with the same sponsor, whether
or not the event occurred in the current trial. Line list-
ings will be sent to sites every 3 months and any new
SUSARs will be discussed at each TMG meeting.
Development safety update reports SITU, on behalf of
the chief investigator and sponsor, will submit (in
addition to the expedited reporting noted above) de-
velopment safety update reports once a year through-
out the clinical trial, or on request, to the competent
authority (MHRA in the UK), the relevant ethics
committee, the Health Research Authority (where re-
quired) and the sponsor. The report will be submitted
within 60 days of the developmental international
birth date of the trial each year until the trial has
been declared as ended.
Notification of deaths In the unlikely event of a death,
the site must complete a notification of death form and
send it to the trial office within 24 h of the site becoming
aware of the event. If the death is the outcome of an
SAE, then it must be recorded on both an SAE form
(within 24 h) and on a notification of death form.
Pregnancy Female participants of childbearing potential
will be counselled appropriately by the PI or Co-I during
the clinic visit and they will be asked to use a reliable
method of contraception (e.g. hormonal contraceptive
patch, intrauterine device, physical barrier or abstinence,
if that is the preferred and usual lifestyle of the patient)
for the duration of the trial.
IMP and placebo arms If a female participant becomes
pregnant during the 3-month active IMP or placebo
period, a completed trial-specific pregnancy reporting
form should be sent to the secure email address situ.ox-
ford@nhs.net within 24 h of the site becoming aware of
the event. The local PI will respond to any queries raised
by the trial office as soon as possible. The participant
should be unblinded and told to stop taking the medica-
tion, but will be asked to remain in the study, and they
will be followed up as per the protocol. The site should
complete a change of status CRF and send it to the
MACRO trial office.
If a female participant becomes pregnant outside of
the 3-month active or placebo period, the site must
complete a pregnancy notification form and submit it to
the trial office. No further action is required by the site.
ESS arm If a female participant becomes pregnant be-
fore receiving ESS, the participant should be withdrawn
from trial treatment, but will be asked to remain in the
trial and to undergo trial follow-up as per the protocol.
The site should complete a discontinuation CRF and a
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change of status CRF and send these to the MACRO
trial office.
If a female participant becomes pregnant after receiv-
ing ESS, the site must complete a pregnancy notification
form and submit it to the trial office. No further action
is required by the site and the participant will be
followed up for the trial as per this protocol.
Overdoses Sites will record details of reported over-
doses of the IMP or the placebo on the deviation log
and inform the trial manager at OCTRU as soon as
possible after being made aware of the information.
An overdose is defined as three or more tablets of
the IMP or placebo in 24 h for 1 day or longer. If an
overdose has taken place, the patient will suspend
medication for at least 48 h, and resume the previous
dose as soon as possible afterwards, at the discretion
of the PI. If an AE occurs and it is deemed to be
more severe than expected (see recording of adverse
events above), the site must complete an AE CRF. If
an SAE has not occurred, the patient may continue
in the trial.
If the event satisfies the definition of a SAR, the site
must also complete an SAE form and the SAE reporting
procedure should be followed. The trials office will no-
tify the sponsor that an overdose associated with a SAE
has occurred.
Ethics and dissemination
Protocol amendments
The sponsor will ensure that the trial protocol including
any agreed amendments, PIS, consent form, GP letter
and supporting documents have been approved by the
appropriate regulatory body (MHRA in UK) and an ap-
propriate research ethics committee, prior to any partici-
pant recruitment. Amendments will not be implemented
prior to receipt of the required approvals.
Consent
Informed consent will be obtained from all participants.
Each potential participant will be telephoned by the RN
or RP at least 48 h after being given the MACRO PIS.
The RN or RP will answer any initial questions about
the trial over the phone, and also invite the patient to re-
turn to the clinic to discuss their possible participation
in the MACRO trial in more depth. The medical notes
must record when and what version of the PIS was given
to the participant.
The follow-up outpatient clinic appointment can by
conducted by the PI, Co-I, RN or RP. As well as discuss-
ing details of the MACRO trial, the following elements
of the consent process should be outlined:
1. A trial-specific ECG must be carried out to confirm
eligibility and consent is required for this.
2. A pregnancy test must be undertaken by females
of childbearing potential and consent is required
for this.
3. The patient will be requested to consent to
providing their email address and mobile phone
number to enable the electronic completion of
PROM questionnaires and resource-use diaries. If
the patient does not consent to completing the
documentation electronically, they will be asked in-
stead to provide their home address and telephone
number so that the MACRO trial office can send
the PROM questionnaires and resource-use diaries
by post.
4. The participant has the option to consent to being
contacted in the future about the MACRO trial or
participating in other research studies (e.g. by
giving tissue, blood or mucus samples).
5. The participant has the option to consent to an
interview with a qualitative researcher as part of the
mixed-methods evaluation.
6. The participant has the option to consent to
being followed up annually for up to 5 years as
part of the larger MACRO programme of work.
Participants participating in the long-term follow-
up will be requested to complete the SNOT-22
and EQ-5D-5 L validated questionnaires, and a
short questionnaire online (a paper version is
also available).
A trained RN or RP, the local PI, the Co-I or an-
other appropriately qualified member of the research
team will obtain informed consent. The person taking
informed consent will be trained on good clinical
practice and will be suitably qualified and experi-
enced. They will have been delegated this duty by the
chief investigator or PI, which will be recorded on
the staff signature and delegation log. The investigator
or designee will explain to the patient that they are
under no obligation to enter the trial and that they
can withdraw at any time during the trial without
providing a reason. No clinical trial procedures will
be conducted prior to the participant giving consent
by signing the informed consent form. Consent will
not denote enrolment into the trial.
A copy of the signed informed consent form will be
given to the participant. The original signed form will be
retained in the trial file at the site and a copy placed in
the medical notes. The PIS and informed consent form
will be reviewed and updated if necessary during the
trial (e.g. where new safety information becomes avail-
able) and participants will be re-consented as
appropriate.
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Ancillary and post-trial care
At the completion of the trial, the patient will receive
the normal clinical care provided by the primary-care
physician and treating ENT surgeon.
Dissemination policy
As part of the wider body of work of the MACRO
programme, we anticipate dissemination through traditional
channels, including conference presentations, abstracts and
open-access peer-reviewed publications. These will be tar-
geted at both specialist and generalist groups, facilitated by
the roles held by the members of our collaboration in rele-
vant professional societies and guideline-producing bodies.
However, beyond informal and specialist publications, we
also plan to use wider communication channels to allow
larger-scale dissemination to the general public. When our
public and patient involvement panel has facilitated a
patient-friendly and comprehensible summary of the study
findings, these will be provided to all study participants by
mail and to the wider public via a study website. We will
maximise non-professional dissemination through a number
of multimedia outlets, including targeted mailshots, press re-
leases to medical and general journalists, health information
websites and communications media, evidence-based inter-
est groups, conference presentations, social media, patient
interest groups and medical charities, such as Fifth Sense
and Asthma UK. We anticipate the results may lead to the
production of new guidelines, which will be made available
through websites such as those of ENT-UK and the Royal
College of Surgeons.
Discussion
The MACRO trial is part of the MACRO programme
funded by the National Institute of Health Research
Programme Grants for Applied Research. The overarching
programme is run by a programme management group.
As listed in Additional file 1: Appendix 1, the trial is man-
aged by the TMG with independent oversight from the
PSC and the DSMC. Day-to-day trial administration is the
responsibility of the trial manager in liaison with the chief
investigators. The trial manager is supported by colleagues
at SITU, which is part of the clinical trials unit of the UK
Clinical Research Collaboration, OCTRU (Additional file
1: Appendix 1). The sites for the trial were selected based
on volume of cases and prior engagement of the PIs in the
research group at the British Rhinological Society, and
also to achieve a mix of teaching hospitals and district
general hospitals over a wide geographical area.
The effectiveness of antibiotics in the treatment CRS
will be established through the trial, which may help to
reduce unnecessary usage and potential morbidity. If
ESS is shown to be clinically effective and cost-effective,
the trial may encourage earlier intervention. In contrast,
if it is shown to be ineffective, then there should be a
significant reduction in surgery rates. The trial results
will feed into the other components of the MACRO re-
search programme to establish best practice for the
management of adults with CRS and design the ideal pa-
tient pathway across primary and secondary care.
Trial status
The current protocol is version 3.0, dated 31 August
2018 (sponsor protocol number 14/0644). The trial is
currently in the pilot phase, having officially commenced
in January 2019 and is due to complete in 2022
(Additional file 2).
Additional files
Additional file 1: Appendix 1. Trial registration, protocol version, funding
details, roles and responsibilities. Appendix 2. Schedule of enrolment,
interventions, and assessments (Spirit guidelines figure). (DOCX 1089 kb)
Additional file 2: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOCX 53 kb)
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